Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: A phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation

Clinical Cancer Research

Volumn 17, Issue 15, 2011, Pages 5152-5160

  Rischin, Danny ^a   Bibby, David C ^b   Chong, Geoff ^c   Kremmidiotis, Gabriel ^b   Leske, Annabell F ^b   Matthews, Clayton A ^b   Wong, Shirley S ^d   Rosen, Mark A ^e   Desai, Jayesh ^f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Bionomics Ltd   (Australia)

^c AUSTIN HEALTH   (Australia)

^d WESTERN HOSPITAL   (Australia)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BNC 105; BNC 105P; TUBULIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLADDER BLEEDING; BLURRED VISION; CANCER INHIBITION; CHILL; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; CONTRAST ENHANCEMENT; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EDEMA; ERYTHEMA; FATIGUE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERESTHESIA; HYPERTENSION; INFECTION; KIDNEY CANCER; LEIOMYOSARCOMA; LIVER FUNCTION TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MESOTHELIOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLEURITIC PAIN; POLYMERIZATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANISOLES; ANTINEOPLASTIC AGENTS; BENZOFURANS; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CELL PROLIFERATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHOSPHORIC ACID ESTERS; PRODRUGS; TUBULIN;

EID: 79961012608     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0937     Document Type: Article

References (17)

1. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990;9:267-82. (Pubitemid 20380383)
2. Cai SX. Small molecule vascular disrupting agents: potential new drugs for cancer treatment. Recent Pat Anticancer Drug Discov 2007;2:79-101. (Pubitemid 46723154)
3. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27. (Pubitemid 38173977)
4. Kremmidiotis G, Leske AF, Lavranos TC, Beaumont D, Gasic J, Hall A, et al. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther 2010;9:1562-73.
5. Kremmidiotis G, Lavranos T, Leske A, Beaumont D, Gasic J, MortimerL, et al. BNC105P is a novel vascular disruption agent that exhibits 100-fold higher potency against activated endothelial cells versusquiescent endothelial cells, translating to a wide therapeutic margin. National Cancer Research Institute (NCRI) conference 2006; Birmingham, UK.
6. Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with Image J. Biophotonics International, U. S. National Institutes of Health 2004;11:36-42. Available from: http://rsb.info.nih.gov/ij/.
7. Taxol® (paclitaxel) injection prescribing information, 2007 (July), Bristol-Myers Squibb Company, Princeton, NJ.
8. Yee KWL, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, et al. Phase 1 study of ABT-751, a novel microtubule inhibitor, inpatients with refractory hematologic malignancies. Clin Cancer Res 2005;11:6615-24. (Pubitemid 41339002)
9. Fox E, Maris JM, Widemann BC, Meek K, Goodwin A, Goodspeed W, et al. A phase 1 study of ABT-751, an orally bioavailable tubulininhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 2006;12:4882-7. (Pubitemid 44338575)
10. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16. (Pubitemid 34651387)
11. Rustin GJS, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, et al. Phase I clinical trial of weekly combretastatin A4 phosphate. J Clin Oncol 2003;21:2815-22.
12. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the anti-vascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magneticresonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428-38. (Pubitemid 46621821)
13. Clinical investigation brochure for BNC105P, 2010 (version 5: July 22), Bionomics Ltd.
14. O'Connor JPB, Jackson A, Parker GJM, Jayson GC. DCE-MRI biomarkersin the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007;96:189-95. (Pubitemid 46160619)
15. Meany HJ, Sackett DL, Maris JM, Ward Y, Krivoshik A, Cohn SL, et al. Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma celllines and on tubulin polymerization in vitro. Pediatr Blood Cancer 2010;54:47-54.
16. Lickliter JD, Francesconi AB, Smith G, Burge M, Coulthard A, Rose S, et al. Phase I trial of CYT997, a novel cytotoxic and vascular-disruptingagent. Br J Cancer 2010;103:597-606.
17. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006;24:1491-8. (Pubitemid 46638769)